Ropinirole implant - Titan Pharmaceuticals

Drug Profile

Ropinirole implant - Titan Pharmaceuticals

Alternative Names: Ropinirole hydrochloride implant - Titan Pharmaceuticals; Ropinirole hydrochloride/ethylene vinyl acetate - Titan Pharmaceuticals

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Titan Pharmaceuticals
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 07 Sep 2017 Chemical structure information added
  • 30 Aug 2017 Titan receives SBIR grant from the National Institute of Neurological Disorders and Stroke for long-term, non-fluctuating dopamine agonist development in Parkinson′s disease
  • 30 Aug 2017 Phase-I/II clinical trials in Parkinson's disease in USA (SC) (NCT03250117)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top